Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $14.00

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $12.25.

A number of equities research analysts have recently commented on SANA shares. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday. They set a “buy” rating and a $7.00 price target for the company. Finally, HC Wainwright boosted their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th.

Insider Buying and Selling at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now directly owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 31.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Sana Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC acquired a new stake in Sana Biotechnology in the fourth quarter valued at $25,000. Tower Research Capital LLC TRC increased its stake in Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after purchasing an additional 10,548 shares during the last quarter. Syon Capital LLC bought a new stake in Sana Biotechnology during the fourth quarter valued at $27,000. Wilmington Savings Fund Society FSB bought a new stake in Sana Biotechnology during the third quarter valued at $29,000. Finally, Ameriprise Financial Inc. bought a new stake in Sana Biotechnology during the fourth quarter valued at $29,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Trading Up 10.6 %

Shares of SANA opened at $2.93 on Friday. The stock has a market cap of $654.18 million, a P/E ratio of -2.09 and a beta of 1.63. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50. The company has a 50-day moving average of $3.03 and a two-hundred day moving average of $3.25.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.